Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712073 | 1.00 | TDP1 (0.33) | TDP1 | |
| SCHEMBL8977842 | 0.73 | CHEK1 (0.30) | — | |
| SCHEMBL10595796 | 0.73 | — | — | |
| SCHEMBL3986771 | 0.73 | — | — | |
| SCHEMBL3231602 | 0.73 | — | — | |
| SCHEMBL23291651 | 0.63 | CA12 (0.42) | — | |
| SCHEMBL13734808 | 0.62 | KDM4E (0.50) | TDP1 | |
| SCHEMBL12746195 | 0.61 | AURKA (0.37) | — | |
| SCHEMBL31561553 | 0.61 | CHEK1 (0.41) | TDP1 | |
| SCHEMBL23092892 | 0.61 | KDM4E (0.38) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021023858-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | UNIVERSITÉ DE STRASBOURG (FR) | 2021-02-11 | — | — | WO | disclosed |
| EP-2844660-B1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RES INST (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9187484-B2 | Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2844660-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | Southern Research Institute (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20130296298-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013166276-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2013-11-07 | — | — | WO | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2170337-A1 | NOVEL TRIAZOLOPYRIDAZINES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-0029130-B1 | 3,6,7,8-SUBSTITUTED-S-TRIAZOLO(4,3-B)-PYRIDAZINES, THEIR PREPARATION AND COMPOSITIONS COMPRISING THEM | THE DOW CHEMICAL COMPANY (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4526890-A | Respiratory system disorders | THE DOW CHEMICAL COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0029130-A1 | 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them | THE DOW CHEMICAL COMPANY (US) | 1981-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | TDP1 320/4885 |
| US-20130296298-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | LRRK2, PINK1, CLK2 | TDP1 154/4885 |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | TDP1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.